In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

The Changing Face of Medical Technology Innovation

Executive Summary

The dynamics of the medical device innovation ecosystem, which has long been US focused, are shifting to create a more global environment. Here, PricewaterhouseCoopers introduces its Medical Technology Innovation Scorecard - to be unveiled later this fall - that evaluates the innovative capacity and capabilities of nine countries, all current or emerging leaders in medical technology, in order to track global shifts in device innovation.

You may also be interested in...



FTC ‘Organic’ Guidance Could Help To Curtail Litigation; Comments On 'Green Guides' Update Due 24 April

The US Federal Trade Commission is accepting comments through 24 April on potential updates to its Guides for the Use of Environmental Marketing Claims, aka “Green Guides,” including on whether it should address “organic” product advertising. Angela Diesch, a partner at law firm Amin Talati Wasserman, discusses.

Supreme Court Seems Ready To Uphold Ruling Against Amgen’s Anti-PCSK9 Antibody Patents

Justices question what Amgen’s invention covers in its dispute with Sanofi. They appear inclined to uphold Federal Circuit’s standard for enablement despite potential negative impact on genus claims.

Vaccine Decisions: US FDA And CDC Weigh New Vaccines For Diseases From Dengue To RSV

Pink Sheet infographic show US regulatory forecast for the many new vaccines facing the twin tests of FDA approval and CDC recommendation, which are both needed to effectively access the US commercial marketplace.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

IV003550

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel